Basic mechanisms of motor fluctuations
- PMID: 8047256
Basic mechanisms of motor fluctuations
Abstract
Patients with Parkinson's disease generally have a smooth clinical response from levodopa therapy for the first 3 to 5 years. Motor fluctuations later become noticeable and may ultimately give way to unpredictable responses to treatment. Mechanisms responsible for motor fluctuations are not fully understood, but can be separated into three groups: (1) central pharmacokinetics, or delivery of dopamine from the presynaptic to the postsynaptic receptor; (2) peripheral pharmacokinetics, or delivery of levodopa from an exogenous source to the brain; and (3) pharmacodynamics, or alterations in the interactions between dopamine and the striatal receptor. Changes in central pharmacokinetics caused by diminished presynaptic dopamine storage capacity probably account for early end-of-dose "wearing-off." As patients lose further storage capacity, peripheral levodopa pharmacokinetics may play an important role in the fluctuation response from erratic gastric emptying or variables that change gut-to-blood and blood-brain barrier transport. Finally, erratic motor responses (eg, the "on-off" phenomenon) in advanced Parkinson's disease may be caused in part by alterations at the striatal dopamine receptor.
Similar articles
-
Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.Brain. 2004 Apr;127(Pt 4):888-99. doi: 10.1093/brain/awh102. Epub 2004 Feb 11. Brain. 2004. PMID: 14960500
-
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.Ann Neurol. 1994 Jul;36(1):27-31. doi: 10.1002/ana.410360108. Ann Neurol. 1994. PMID: 8024257
-
Treating motor fluctuations with controlled-release levodopa preparations.Neurology. 1994 Jul;44(7 Suppl 6):S23-8. Neurology. 1994. PMID: 8047257 Review.
-
Various aspects of motor fluctuations and their management in Parkinson's disease.Neurology. 1994 Jul;44(7 Suppl 6):S29-34. Neurology. 1994. PMID: 8047258 Review.
-
Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.J Pharm Pharm Sci. 2002 May-Aug;5(2):146-61. J Pharm Pharm Sci. 2002. PMID: 12207867
Cited by
-
Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.Clin Pharmacokinet. 2001;40(5):383-93. doi: 10.2165/00003088-200140050-00005. Clin Pharmacokinet. 2001. PMID: 11432539 Clinical Trial.
-
Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.Drugs Aging. 1997 May;10(5):332-40. doi: 10.2165/00002512-199710050-00002. Drugs Aging. 1997. PMID: 9143854 Review.
-
Treatment of dysautonomia in extrapyramidal disorders.Ther Adv Neurol Disord. 2010 Jan;3(1):53-67. doi: 10.1177/1756285609348902. Ther Adv Neurol Disord. 2010. PMID: 21180636 Free PMC article.
-
Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.Br J Pharmacol. 1999 Aug;127(7):1696-702. doi: 10.1038/sj.bjp.0702673. Br J Pharmacol. 1999. PMID: 10455328 Free PMC article.
-
Concentration-effect relationship of levodopa in patients with Parkinson's disease.Clin Pharmacokinet. 1995 Oct;29(4):243-56. doi: 10.2165/00003088-199529040-00004. Clin Pharmacokinet. 1995. PMID: 8549026 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials